Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14537729 | 1.00 | EGFR (0.54) | EGFRPIM1ELANEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7460 | 0.99 | EGFR (0.53) | EGFRPIM1ELANEMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL29658548 | 0.99 | EGFR (0.53) | EGFRPIM1ELANEMEN1KMT2A | |
| SCHEMBL13452107 | 0.87 | EGFR (0.53) | EGFRPIM1ELANEMEN1KMT2A | |
| SCHEMBL17278322 | 0.86 | EGFR (0.52) | EGFRPIM1ELANEMEN1KMT2A | |
| SCHEMBL21573136 | 0.86 | EGFR (0.52) | EGFRPIM1ELANEMEN1KMT2A | |
| SCHEMBL21886965 | 0.85 | EGFR (0.51) | EGFRPIM1ELANEMEN1KMT2A | |
| SCHEMBL22873368 | 0.85 | EGFR (0.51) | EGFRPIM1ELANEMEN1KMT2A | |
| SCHEMBL11395596 | 0.85 | EGFR (0.51) | EGFRPIM1ELANEMEN1KMT2A | |
| SCHEMBL11429902 | 0.85 | EGFR (0.51) | EGFRPIM1ELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0007403-B1 | 5,12-DIHYDROXY-1,2,3,4,6,11-HEXAHYDRO-2,6,11-TRIOXONAPHTHACENES AND THEIR SYNTHESIS | THE UNIVERSITY OF KANSAS (US) | 1982-11-24 | — | — | EP | claimed |
| US-4244880-A | Anthracycline synthesis | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1981-01-13 | — | — | US | claimed |
| US-4215062-A | Anthracycline synthesis | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1980-07-29 | — | — | US | claimed |
| EP-0007403-A1 | 5,12-dihydroxy-1,2,3,4,6,11-hexahydro-2,6,11-trioxonaphthacenes and their synthesis | THE UNIVERSITY OF KANSAS (US) | 1980-02-06 | — | — | EP | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS, LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240050415-A1 | DACLATASVIR FOR USE IN TREATING LUNG AND PROSTATE CANCER | HENRY FORD HEALTH SYSTEM (US) | 2024-02-15 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS LLC (US) | 2022-07-07 | — | — | US | disclosed |
| US-11141459-B2 | Pharmaceutical composition comprising Lefty | GRANT LABS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20090175869-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | ASCENTA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | ASCENTA THERAPEUTICS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2008-01-24 | — | — | US | disclosed |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | QUINTESSENCE BIOSCIENCES, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| EP-0007403-B1 | 5,12-DIHYDROXY-1,2,3,4,6,11-HEXAHYDRO-2,6,11-TRIOXONAPHTHACENES AND THEIR SYNTHESIS | THE UNIVERSITY OF KANSAS (US) | 1982-11-24 | — | — | EP | disclosed |
| US-4244880-A | Anthracycline synthesis | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1981-01-13 | — | — | US | disclosed |
| US-4215062-A | Anthracycline synthesis | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1980-07-29 | — | — | US | disclosed |
| EP-0007403-A1 | 5,12-dihydroxy-1,2,3,4,6,11-hexahydro-2,6,11-trioxonaphthacenes and their synthesis | THE UNIVERSITY OF KANSAS (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | EGFR 358/4885PIM1 961/4885ELANE 2347/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885PIM1 305/4885ELANE 2275/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | EGFR 1/4885PIM1 305/4885ELANE 2275/4885 |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | BCL2, BAX, PHLPP2 | EGFR 4322/4885PIM1 1373/4885ELANE 2794/4885 |
| US-20220213054-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885PIM1 305/4885ELANE 2275/4885 |
| US-20090175869-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | BCL2, BAX, BAD | EGFR 4411/4885PIM1 1182/4885ELANE 3427/4885 |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885PIM1 305/4885ELANE 2275/4885 |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | XIAP, BIRC5, BIRC3 | EGFR 4170/4885PIM1 2139/4885ELANE 484/4885 |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | RNASE1, RNASEL, RNASEH1 | EGFR 2869/4885PIM1 2913/4885ELANE 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.